The Therapeutic Effects of Lithium in Affective Disorders by Stankovska, Gordana & Dimitrovski, Dimitar
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.3, No.11, 2013 
 
125 
The Therapeutic Effects of Lithium in Affective Disorders 
 
Gordana Stankovska, Dimitar Dimitrovski 
 Faculty of Medicine, Department of Psychiatry,State Univesity of Tetova, Macedonia 
                                     E-mail of the corresponding author: gorstankovska@yahoo.com  
 
Summary 
Objective The main objective of this research was to explore the psychopathological aspects of affective 
disorder and the clinical effects of pharmacological treatment with lithium.   
Materials and Methods: The study involved 40 patientsts (26 females, 14 males) with an average age 45,5 
years, hospitalized in the Psychiatric Hospital in Skopje and the Department of Psychiatry of Clinical Hospital in 
Tetovo, with a clinical diagnosis of affective disorder. The diagnosis of affective disorder is set against the 
classification DSM-IV (Diagnostic and Statistical Manuel of Mental Disorder). All subjects were under 
pharmacological treatment with lithium carbonats whose dose depends of the clinical subentitet, the beginning 
and duration of the disorder. Clinical-laboratory examinations included: history and clinical status, determination 
of serum lithium concentration. The serum lithium concentrations were measured by Ion-Selective Electrode 
(ISE) with the COBAS/INTEGRA 700 analyzer.  
Results: The results of the research show us that patient with acute phase of mania had higher concentration of 
lithium in serum compared with patients with bipolar affective psychosis. Also the patients who received 
combination theraoy (lithium/neuroleptic or antidepressant) mean values of lithium in serum range 1,89 mmol/L 
compared to patients who only used lithium whose mean values are 0,82 mmol/L. Pearson correlation between 
two groups was significantly significant at the level of 0,01.  
Conclusions: With the regular and continued use of lithium in affective disorders and good co-operation with 
the patient during the therapy could be reduced the relapses of the disease and improved the quality of life of the 
person. 
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Introduction 
Bipolar disorders, also called maniaco-depressive psychosis, are a group of disorders that cause mood fluctions 
characterized by phases of depression and phases of mania. Manic episodes are characterized by a predominantly 
elevated, expansive or irritable mood that presents as a prominent or persistent part of the illness. Manic patients 
classically have abundant resources of energy and engage in multiple activities and ventures. At baseline and 
berween episodes, the bipolar manic patient may indeed function at a high level of productivity, particularly in 
areas requiring creative talent. The mood is often accompanied by a sense of absolute concietion or certitude, 
usually involving a se;f-perceived talent or perception, but occasionally centering around more metaphysical and 
cosmic matters. 
On the other hand a variety of studies have distinguished depressed individuals with prominent psychomotor 
retardation and anhedonia from those who evidence psychomotor activation, guilt, anxiety, depressive thinking 
and depressive affect. Patients with bipolar disorder, mixed type, may likewise exhibit features of severe 
depression, but will also present manic symptoms.   
Mood changes are a normal part of life. How ever, with bipolar disorders, the awings are more extreme. They 
become so intense, that the person does not realize thas he/she is not behaving normally or the person suffers as 
much from depression that he/she is paralyzed and overwhelmed by suicidal thoughts. These states may cause 
problem at work, with the family, with finances and sometimes with legal authoritez. 
The etiology of affective psychosis is very complex (Lenox, 2003; Paunovic, 1999). Today generally is accepted 
hypothesis for multifactorial geneses for this group of psychosis. Among most important etiologic factors 
include: genetic, biochemical, neuropsychological and psychological, as well as a great number of socio-cultural 
and psychosocial factors. 
Treatment of bipolar disorder depends upon the specific form of behavioral disorder. Several definitions for 
mood stabilizer have been proposed. In the most definition, three models of clinical action for bipolar disorder 
are required: antimanic, antidepressive and prophylactic effects. Lithium is the first and only mood stabilizer in 
which these three reactions were confirmed and thus it is the first drug of choice in the treatment for bipolar 
disorder in spite of availability of alternative mood stabilizers, in less stringent criteria. However, a significant 
percentage of bipolar patients show no or a partial response to lithium treatment. Selecting an appropriate mood 
stabilizer is still a matter of great concern for many clinicans. 
Ever since Cade (1949) observed the antimanic effect of lithium and Schow et al. (1954) conducted extensive 
clinical studies to elucidate its application in the treatment of affective disorders, reports continue to appear in 
the world literature. 
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Hartigan (1963) for the first time reported on the prophylactic effects of lithium on manic as well as depressive 
episodes. This property, of lithium was later on confirmed by studies comparing frequency and intensity of 
episodes of mania and depression before and after administration of lithium (Dodan, 2003; Kalicanin, 2004). 
Bertelson (2007) confirmed that treatment with lithium reduced the number of relapses and hospital admissions. 
However, experience over the following 30 years indicated that lithium carbonate is the best mood stabilizer for 
this kind of psychosis. 
Lithium is a metallic element widespread in nature. In psychiatry, lithium is used in the form of easily 
dissociating salts and the most common preparations are lithium carbonates and citrates. The therapeutic action 
is displayed by lithium cations, which are easily absorbed in the gastrointenstinal tract after oral intake and are 
not bind by plasma proteins. The maximum blood concentrations appear 2-4 hours after the intake (Carno et al., 
2001). 
Jope (1999) showed that lithium salts were more effective in the concentration of 0,8-1,2 mmol/L in the plasma 
than at the level of 0,4-0,6 mmol/L. However, higher lithium concentrations caused the occurrence and 
intensification of side effects of lithium therapy. So monitoring serum lithium concentrations is accepted as a 
necessary feature of lithium therapy, because the consequences of lithium toxicity can be quite serious. 
So the aim of the present study is to examine the effect of treatment with lithium in patients with affective 
disorder and relationship between the clinical picture and serum lithium concentration. 
 
Materials and methods 
Sample collection 
The study included 40 patients (26 females, 14 males) with a mean age of 45,5 years and with a clinical 
diagnosis of affective disorder (unipolar mania, unipolar depression and bipolar disorder). The diagnosis of 
affective disorder is set  
against the classification DSM-IV (Diagnostic and Statistical Manula of Mental Disorder) published by the 
American Psychiatric Association (APA, 2004).  
All the subjects were treated hospitality in the Psychiatric Hospital in Skopje and the Department of Psychiatry 
of Clinical Hospital in Tetovo. The patients had not clinical evidence of a medical or neurological illness that 
could be responsible for psychiatric symptoms, not any history of alcohol or drug abuse, head trauma, neurologic 
or somatic disorder. The patients have been treated with lithium carbonats, neuroleptic medication and 
antidepressants. 
Before patient was started on lithium therapy in each patient these following biochemicalmeasures have been 
conducted: 
* Electrocardiogram 
* Complete haemogram and urianalysis. 
* Determination of blood urea,  blood sugar, serum creatinine, serum cholesterol, serum electrolytes (Na
+
, K
+
). 
* Liver function. 
* Weight charting.          
We divided the sample in the two groups: 20 patients with acute symptoms of affective disorder and 20 patients 
with chronic form of the same disorder. In the first group daily dose of lithium was from 900-1800 mgr. in 
combination with neuroleptic or antidepressant, while in the second group the daily dose of lithium was 600-
1200 mgr. After 48 to 72 hours of commencement of lithium blood samples were drawn twelve hours after the 
last oral dose of lithium. For the first six months the patients were reviwed once in 2-3 weeks and later in longer 
intervals. During each review serum lithium was estimated, besides recording clinical assessment, side-effects, 
weight charting and use of other concomitant medication. Every patients was informed about possible side 
effects and an instruction sheet for the same provided. 
Lithium determination by Ion – Selective Electrode  
The serum lithium was estimated by the Ion-Selective Electrode (ISE module) with the COBAS/INTEGRA 700 
chemical analyzer from Roche Diagnostics (Switerland). All the analyses were done at the Department of 
Clinical Biochemistry in Skopje. 
Lithium is measured in the COBAS/INTEGRA 700 Na/K/Li analyzer by the interaction of lithium with 
ionophore contained in a polyvinyl chloride membrane. We measured sodium by a sodium-sensitive glass 
capillary and potassium by use of a polyvinyl chloride/valinomycin electrode enbrane.  
The instrument aspirated 120 µL of serum into sequential chambers that housed the sodium, potassium, lithium 
and reference electrodes. The instrument automatically performed a one-point calibration after each sample and 
initiated a three-point calibration every 3 hours. Daily and weekly maintaince was performed as specified in the 
operation manual. Serum specimens analyzed in the ISE instrument required no pre-treatment. The reference 
values for lithium were 0,5-1,5 mmol/L.  
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Results 
 As shown in table 1 the majority of patients had bipolar psychosis (60%) followed by unipolar-manic episode 
(40%). 
      Table1. Distribution of patients according to the type of affective disorder 
    Diagnosis N % 
Manic phase 16 40 
Bipolar disorder 24 60 
Total 40                 100 
 
Also we found that most of patients 25 (62,5%) used lithium together with neuroleptic or antidepressant, while 
15 (37,5%) patients were treated only with therapy of lithium carbonats (Table 2). 
        Table2. Distribution of patients according to the form of therapy 
Therapy N % 
Lithium 15 37.5 
Lithium/neuroleptic/antidepressant 25 62.5 
Total 40             100,00 
       
Manic patients showed significantly higher mean lithium serum levels as compared with the group of subjects 
with bipolar psychosis (Table 3). The correlation of statistical significance by Pearson between the two groups is 
at the level of 0,01. 
         Table3. Mean serum lithium levels and the type of affective disorder 
Li mmol/l Manic phase Bipolar disorder 
N 16 24 
Mean 1.767 1.312 
Std. Deviation 0.581 0.640 
Pearson Correlation 1 0.784** 
**. Correlation is significant at the 0.01 level  
From the Figure 1 it is clear that patients in the manic phase of affective disorder had higher values of lithium in 
blood, because they had been treated with higher doses of lithium carbonats. It is very important, because if 
patients in this phase take the lowest doses of lithium, the risk of relapse of illness is very high. 
  
 
                Figure1. Mean serum lithium levels and the type of affective disorder 
Table 4 shows the mean serum lithium levels and relationship between the duration of psychoses and serum 
levels in the two lithium intake groups. There were significant differences in mean serum levels of lithium in 
comparisons among two subgroups of patients with affective disorders. 
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 Table4. Mean serum lithium levels according to the duration of psychosis 
Li mmol/l Mean Std. Deviation N Pearson Correlation 
6 months to 1 year 2.078 0.238 20 1 
1 to 5 years 0.911 0.308 20 0.903** 
**. Correlation is significant at the 0.01 level  
In our study we observed that patients in acute phase of affective disorder had higher concentration of lithium in 
serum compared with chronic group (p<0,01) (Figure 2). There is an interesting trend, which warrants further 
investigation for lithium to rise with duration of hospitalization 
.       
 
           Figure2. Mean serum lithium levels according to the duration of psychosis 
Antipsychotic or antidepressant drugs are used extensively in the maintence treatment of patients with bipolar 
disorder. For rapid-cycling bipolar, the combination therapy (lithium/neuroleptic or antidepressant) stabilize 
mood swings. So in our studied population we observed that in patients who received lithium together with the 
other psychopharmacological drugs mean values of serum lithium range 1,895 mmol/L compared to patients 
who used only lithium where the mean values of serum lithium was only 0,827 mmol/L (Table 5). 
       Table5. The form of therapy and mean serum lithium levels 
Li mmol/l  Lithium Li/neuroleptic/antidepressant 
N 15 25 
Mean 0.827 1.895 
Std. Deviation 0.226 0.460 
Pearson Correlation 1 0.819** 
**. Correlation is significant at the 0.01 level  
This investigation suggest that longterm treatment with antipsychotic drugs enables a proportion of patients with 
bipolar disorder to experience periods of greater stability. The mechanisms involved may be primarly antimanic, 
but result in less aubseguement depression, as a argued for lithium. 
 
Discussion 
Our emotional goal is to be happy. Unfortunately some people can not reach their goal of happiness. This 
disorder is called depression. Not only to those who suffer depression try to find ways to become happy again, 
but also others who want to help are in a constant search to find a means to offset depression. One way to offset 
depression is through medication and one of the many medications is lithium. 
Lithium has been found to be effective in manic-depressive disorder. Manic-depressive disorder (also called 
bipolar or affective disorder) is a mood disorder in which a person alternates between depression and mania. 
Mania (or a manic episode) is a mood disorder in which a person tends to be hyperactive and wildly optimistic. 
A person suffering from a manic phase is overtalkative, overactiuve, elated, loud and hard to understand. He or 
she has little need for sleep, shows fewer sexual inhibitions and has grandiose optimism. Lithium aids to contol 
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manic episodes, but is not as effective at controlling depressive episodes. This is why patients who respond to 
lithium most effectively are those with bipolar psychosis and a predominant behavior of mania. Patient whose 
behavior alternates between manic and depressive often, do less well with lithium treatment (Bohacek, 1986; 
Compton, Nemeroff, 2000; Siever, 1987; Solomon et al., 1996). 
A large number of clinical research studies on psychopathological predictors of lithium response has been 
reported. As predictors of positive lithium response, the following have been reported: euphoric mood, small 
number of episodes, maniac-depression-free interval pattern in the illness course and positive family history 
(Chand, Marroo and Sharan, 2004; Maj, Pirozzi and Magliano, 1996). In contrast, the following have been 
confirmed as predictors of poor lithium response: mixed states, psychotic features, depression-mania-free 
interval pattern, rapid cycling and comorbid alchohol and/or drug abuse (Carrol, 1999; Maj, Pirozzi and Starace, 
1989).  
During our research we followed serum levels of lithium in blood during initial treatment (acute episode of the 
disease) and maintence treatment (patients with chronic disease). We found that during continuously and long-
term use of lithium response is positive in all subjects, but lithium especially shows its activity in the early stages 
of acute mania states. In all the two groups of lithium intake, a dose range of 300 mg to 1800 mg was sufficient 
to bring about the desired clinical response and an increase in dosage of lithium is accompanied by a 
corresponding increase in the values of level which always remained within the recommended therapeutic range, 
through mostly on the lower side. The clinic research suggest that the levels from 0,4 to 0,8 mg would suffice for 
prophylaxis, thought recognizing the need for higher levels of 0,6 – 1,2 mg for controlling acute manic episodes. 
Also patients who received combination therapy (lithium with the other psychopharmacological drugs) had 
higher concentration of lithium in serum. At the same time determining the concentration of lithium in serum 
serves as a valid indicator for monitoring the dose. We would expect that patients treated with a combination of 
lithium and neuroleptic/antidepressant drugs would respond significantly better than patients treated with either 
drug alone. 
Mood disorders can be chronic and recurrent and they are associated with high preterm mortality due to a high 
risk of suicidal attempts and increased exposure to somatic illnesses compared o rhe general population (Swann, 
Bowden and Morris, 1997). Mode disorders have serious consequences, like the deteriorated quality of family 
and professional life, amoung patients and their families.  
Also lithium does not cure recurrent affective disorder, it must be given continuosly to prevent relapses (Angst 
and Wels, 1970). It is essential that the patients understand that further attacs may occur – these episodes may be 
safely treated by other methods, but lithium treatment should continue.  
 
Conclusions 
Although has been used in psychiatry for many years, during which new medications producing similar effects 
have been introduces, it remarks a medicine of the first choice long-term stabilizing therapy, in the light of 
current research, lithium monotherapy in acute manic conditionsor severe and modeate depressive episodes is 
not ecommended. It is known that psychiatrist can prevent complications related to lithium therapy if they 
continually monitoring of its plasma level and observing the patient to detecting side effects. 
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